<DOC>
	<DOCNO>NCT00493324</DOCNO>
	<brief_summary>A vaccine cause immune system produce antibody ( immune response ) specific germ protect patient . This study evaluate immune response pneumococcal vaccine adult Alefacept-treated chronic plaque psoriasis .</brief_summary>
	<brief_title>Study Evaluate Immune Response Pneumococcal Vaccine Alefacept-treated Adults With Chronic Plaque Psoriasis</brief_title>
	<detailed_description>This 1 arm study design evaluate immune response pneumococcal vaccine adult Alefacept-treated chronic plaque psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subject chronic plaque psoriasis Subject least 5 % body surface area affect psoriasis Skin disorder plaque psoriasis affect area Previously immunize pneumococcal vaccine Subject pustular erythrodermic psoriasis Subject immunocompromised Six herpes simplex virus outbreak per year History malignancy , chronic serious infection hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>alefacept</keyword>
	<keyword>polyvalent pneumococcal vaccine</keyword>
	<keyword>Immunization</keyword>
</DOC>